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ABSTRACT
Background
Lenalidomide is an effective new agent for the treatment of patients with myelodysplastic
syndrome (MDS), an acquired hematopoietic disorder characterized by ineffective blood cell
production and a predisposition to the development of leukemia. Patients with an interstitial
deletion of Chromosome 5q have a high rate of response to lenalidomide, but most MDS
patients lack this deletion. Approximately 25% of patients without 5q deletions also benefit
from lenalidomide therapy, but response in these patients cannot be predicted by any
currently available diagnostic assays. The aim of this study was to develop a method to predict
lenalidomide response in order to avoid unnecessary toxicity in patients unlikely to benefit
from treatment.
Methods and Findings
Using gene expression profiling, we identified a molecular signature that predicts
lenalidomide response. The signature was defined in a set of 16 pretreatment bone marrow
aspirates from MDS patients without 5q deletions, and validated in an independent set of 26
samples. The response signature consisted of a cohesive set of erythroid-specific genes with
decreased expression in responders, suggesting that a defect in erythroid differentiation
underlies lenalidomide response. Consistent with this observation, treatment with lenalidomide
promoted erythroid differentiation of primary hematopoietic progenitor cells grown in vitro.
Conclusions
These studies indicate that lenalidomide-responsive patients have a defect in erythroid
differentiation, and suggest a strategy for a clinical test to predict patients most likely to
respond to the drug. The experiments further suggest that the efficacy of lenalidomide, whose
mechanism of action in MDS is unknown, may be due to its ability to induce erythroid
differentiation.
The Editors’ Summary of this article follows the references.
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Myelodysplastic syndrome (MDS) is an acquired, neoplastic
disorder of hematopoietic stem cells characterized by
ineffective and dysplastic hematopoietic differentiation and
a high rate of progression to acute leukemia. Therapeutic
options for patients with MDS are limited: bone marrow
transplantation has curative potential but is only an option
for a small minority of patients, high-dose chemotherapy has
poor efﬁcacy and high toxicity, and other pharmacological
therapies have, until recently, had limited beneﬁt [1,2]. The
thalidomide derivative lenalidomide (Revlimid, CC-5013),
however, has recently demonstrated promise for the treat-
ment of MDS [3,4]. Strikingly, lenalidomide response is most
common in patients with deletions of the long arm of
Chromosome 5. Speciﬁcally, a recent Phase II study of the
activity of lenalidomide in patients with low- or intermediate-
1–risk MDS and 5q deletions, showed that 76% of patients
had a decreased need for blood transfusions and 61%
achieved complete resolution of cytogenetic abnormalities
[3]. This effect represents the most signiﬁcant clinical
response ever seen in MDS.
Unfortunately, the vast majority of MDS patients (over
80%) lack 5q deletions, and only 26% of such patients
respond to lenalidomide [5]. It is not clear which patients
without 5q deletions should receive the drug, particularly
given the toxicities of lenalidomide (primarily neutropenia
and thrombocytopenia), which are severe in some cases [3–5].
In order to limit exposure of lenalidomide to the patients who
are most likely to beneﬁt, a biological predictor of response is
needed. Finding such predictors is particularly challenging
because both the mechanism of lenalidomide activity in MDS
and the molecular basis of MDS are unknown. We took a
genome-wide view of the problem and used gene expression
proﬁling to develop a predictor of lenalidomide response.
Materials and Methods
Patient Samples
All samples were obtained from patients treated in Phase II
clinical trials, MDS-002 and MDS-003, studying the efﬁcacy of
lenalidomide in low-risk, transfusion-dependent MDS in
patients without 5q deletions or with 5q deletions, respec-
tively [3,5]. Mononuclear cells from each pretreatment bone
marrow aspirate were obtained following informed consent
from the patient under institutional review board–approved
protocols from Rush Medical School, the University of
Massachusetts Medical School, or the Dana-Farber Cancer
Institute. Mononuclear cells from bone marrow aspirates
were puriﬁed by Ficoll gradient. Cell pellets were dissolved in
Trizol (Invitrogen) and stored at  80 8C (samples from Rush
Medical School and the University of Massachusetts), or were
stored in liquid nitrogen as cell pellets (samples from the
Dana-Farber Cancer Institute). All available samples from
these institutions were included in this study. No samples
were excluded on the basis of clinical parameters. An initial
training set comprised 16 samples from patients without 5q
deletions. An independent test set comprised 13 samples
from patients without 5q deletions. In addition, we analyzed a
set of 13 samples from patients with 5q deletions.
All patients had low- or intermediate-1–risk MDS as
determined by the International Prognostic Score [6], trans-
fusion-dependent anemia requiring greater than two units of
red blood cells every 8 wk, an absolute neutrophil count
greater than 500/ml, and a platelet count greater than 30,000/
ml. Patients with chronic myelomonocytic leukemia (CMML)
with a white blood count greater than 12,000/ml were
excluded. Patients in this study had not received hemato-
poietic growth factors for 14 d prior to the pretreatment
bone marrow aspirate. Patients were treated with lenalido-
mide at a dose of 10 mg/d or 10 mg/d for 21 d in 4-wk cycles.
Hematologic response was determined using a modiﬁed
version of the criteria deﬁned by an international working
group [3,7]. A complete hematologic response was deﬁned as
transfusion independence, the absence of transfusions for 8
wk, and an increase in hemoglobin of greater than or equal to
1.0 g/dl. A minor hematologic response was deﬁned as a 50%
decrease in the number of transfusions that was sustained for
eight consecutive weeks. Responders, in this study, included
patients with either a minor or complete hematologic
response to lenalidomide.
Oligonucleotide Microarrays
RNA was puriﬁed from mononuclear cells using Trizol
(Invitrogen). Linear ampliﬁcation of 20 ng of total RNA was
performed using the Ovation Biotin RNA Ampliﬁcation and
Labeling System (Nugen). Fragmented, labeled cDNA was
hybridized to Affymetrix oligonucleotide microarrays as
described previously [8,9]. Patient samples for the training
set were proﬁled on HG_U133 Plus 2.0 microarrays; samples
for the test set and samples from cells cultured in vitro were
proﬁled using the Affymetrix HTA platform with hybrid-
ization to HG_U133AAofAv2 microarrays. Raw expression
values were normalized using Robust Multiarray Averaging
(RMA) [10]. Microarrays are listed in Table S1, and the
complete dataset is available at http://www.broad.mit.edu/
cancer/pub/Revlimid.
Marker Gene Selection
Raw gene expression values were preprocessed and
normalized using Robust Multiarray Averaging (RMA) [10].
Genes with minimal variation across the dataset were
excluded by discarding genes for which the maximum gene
expression value divided by the minimum value across all
samples was less than two, or if the difference between
maximum and minimum values was less than 100. Marker
genes were ranked using the signal-to-noise metric [9]. For
gene x, the signal-to-noise metric, Sx, is calculated as:
Sx ¼ð l0   l1Þ=ðr0 þ r1Þð 1Þ
where l0 and r0 are the mean and standard deviation for
gene x in class 0, and l1 and r1 are the respective values for
class 1. Statistical signiﬁcance was determined by random
permutation of the class labels [9]. Signiﬁcant markers were
selected using a false-discovery rate (FDR) threshold of 0.1
computed using the Benjamini and Hochberg procedure [11].
Analyses were implemented using the GenePattern software
package [12] using the ComparativeMarkerSelection module
[13].
Gene Set Enrichment Analysis
Gene set enrichment analysis (GSEA) was performed as
described previously [14]. The dataset was converted from
probe sets to gene symbols and analyzed using the java GSEA
package. The input gene set database was comprised of the
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version 2 (MSigDBv2) [14,15]. All gene sets, including both
curated gene sets from MSigDBv2 and the response signature,
are available in Table S4. Gene sets enriched in responder or
nonresponder classes were ranked by normalized enrichment
score, and statistical signiﬁcance was determined by permu-
tation of the gene tags.
Gene Expression–Based Lenalidomide Response Predictor
A predictor of lenalidomide response was created by
comparing the response signature to a reference signature
for each sample. The response signature was deﬁned as the
marker genes of nonresponders compared to responders in
the training dataset (FDR   0.10) that are present on both the
U133 Plus 2.0 and U133AAofAv2 microarrays, and that
increased in expression during terminal erythroid differ-
entiation. The reference signature was deﬁned by taking a list
of previously published control genes that are invariant in
other gene expression datasets [16], and selecting the ﬁve
genes with the smallest standard deviation across samples in
the training dataset. The ﬁve genes in the reference signature
are ACTB, B2M, GAPDH, TXNRD1, and UBE2D2.
In order to predict response to lenalidomide using gene
expression data acquired on different microarray platforms,
gene expression values for each sample were replaced by their
ranks among all features in that sample and then linearly
scaled to the [0, 10,000] range, as described previously [17].
The expression of each gene in the erythroid signature was
divided by the average gene expression for the reference
signature in the corresponding sample. A z-score was
obtained for each gene in the response signature. A single
predictor score was obtained for each sample by averaging
the z-scores for each gene in the response signature. A binary
regression linear model was ﬁt to the predictor score to
determine the location of the class boundary between
responders and nonresponders using the ‘‘glm’’ function in
R [18]. To predict response in the test set of patients without
5q deletions or in the set of patients with 5q deletions, z-
scores were calculated using the mean and standard deviation
for each gene from the training set. The R software that
implements the method described above is available (http://
www.broad.mit.edu/cancer/pub/Revlimid) and as a GenePat-
tern module.
Statistical signiﬁcance of the predictor was assessed using
the proportional chance criterium [19]. Details of this
calculation are included in the Text S1.
Culture of Primary Hematopoietic Progenitor Cells
Cryopreserved human adult bone marrow CD34
þ cells
from normal, healthy donors were obtained from Cambrex
(Poietics; Cambrex). Cells were cultured in Serum Free
Expansion Medium (SFEM; Stem Cell Technologies) supple-
mented with 100 U/ml penicillin/streptomycin, 2 mM gluta-
mine, and 40 lg/ml lipids (Sigma). Erythroid differentiation
was induced in vitro in two steps [20]. For the ﬁrst 7 d, cells
were cultured in the presence of 100 ng/ml stem cell factor
(SCF), 10 ng/ml interleukin-3 (IL-3), 1 lM dexamethasone,
and 0.5 IU/ml erythropoietin (Epo). After 7 d, dexamethasone
was withdrawn and cells were cultured in the same medium
supplemented with 3 IU/ml Epo.
To support both erythroid and megakaryocytic differ-
entiation within the same liquid culture, cells were cultured
in the presence of 50 ng/ml thrombopoietin, 100 ng/ml SCF,
10 ng/ml Il-3, 10 ng/ml IL-6, and 0.5 U/ml Epo. The
concentration of Epo was increased to 3 IU/ml on day 7. To
support both erythroid and myeloid differentiation within
the same liquid culture, cells were cultured in the presence of
25 ng/ml SCF, 10 ng/ml IL-3, 40 ng/ml ﬂt-3 ligand, 15 ng/ml
granulocyte colony stimulating factor (G-CSF), and 0.5 IU/ml
Epo. The concentration of Epo was increased to 3 IU/ml on
day 7. Cells were grown in the presence or absence of
lenalidomide (Celgene Corporation).
Flow Cytometry
Cells were harvested for ﬂow cytometry following 10 d of
liquid culture. Approximately 5 3 10
5 cells were labeled with
phycoerythrin or FITC-conjugated antibodies for 15 min on
ice. Hematopoietic differentiation was assessed using anti-
bodies speciﬁc for the erythroid marker glycophorin A (Gly-
A, CD235a, Clone GA-R2; BD-Pharmingen), the megakaryo-
cyte marker CD41a (Clone HIP8; BD-Pharmingen), and the
myeloid marker CD11b (Clone D12; BD-Pharmingen).
Methylcellulose Colony Assays
Following 72 h of liquid culture in the presence or absence
of lenalidomide, cells were plated on methylcellulose con-
taining Epo, SCF, GM-CSF, and IL-3 (H4434; Stem Cell
Technologies). Colony formation was evaluated following 14
d of culture at 37 8C in a humidiﬁed atmosphere with 5%
CO2. Colonies containing greater than 100 erythroid cells
were scored as burst-forming unit erythroid colonies (BFU-E),
and colonies with greater than 20 granulocytes and mono-
cytes were scored as granulocyte-monocyte colony-forming
units (CFU-GM).
Results
Identification of a Lenalidomide Response Signature
Lenalidomide is an effective treatment for MDS patients
with 5q deletions, but the response rate among patients
lacking the deletion is much lower (26%). Moreover, the
likelihood of response cannot be accurately determined on
the basis of clinical parameters or known molecular assays. In
order to develop a predictor of lenalidomide response, we
examined the genome-wide gene expression proﬁles of bone
marrow aspirate mononuclear cells obtained from patients
with MDS prior to therapy with lenalidomide (Table 1).
Responders did not vary signiﬁcantly from nonresponders
with respect to clinical characteristics such as age, bone
marrow cell counts, or peripheral blood cell counts (Table 2
and the regression model in Text S1).
We compared the gene expression proﬁles of responders
and nonresponders to identify genes that correlate with
lenalidomide response in patients lacking 5q deletions.
Statistical signiﬁcance was estimated by permuting the class
labels, and the FDR was calculated to correct for multiple
hypothesis testing. As shown in Figure 1, 68 probe sets
representing 47 genes were more highly expressed in
nonresponders than responders (at FDR   0.10). A total of
seven probe sets representing six genes were more highly
expressed in responders (FDR   0.10).
To conﬁrm the differential expression of a subset of the
genes using a different platform, we examined the mRNA
levels of seven signature genes in the same samples using
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ﬂuorescent beads. This assay provides a quantitative detec-
tion of each gene in a single multiplexed assay (Figure S1)
[21]. As in the microarray data, each signature gene was
expressed at higher levels in nonresponders than in res-
ponders (Figure S2). These results suggest that a signature of
lenalidomide response is detectable.
Biological Characterization of the Response Signature
To gain insight into the biological meaning of the
lenalidomide response signature, we used GSEA to examine
the expression of a compendium of 1,688 annotated gene sets
representing diverse functional pathways, and asked whether
any of these gene sets were enriched in responder versus
nonresponder samples. The gene sets most signiﬁcantly
enriched in the nonresponder class included those related
to erythroid differentiation. Speciﬁcally, a set of genes
targeted by the canonical erythroid-speciﬁc transcription
factor GATA-1 showed strong enrichment, as did a gene set
representing targets of STAT5A, a transcription factor
activated by the erythroid-speciﬁc erythropoietin receptor.
Gene sets with the most signiﬁcant enrichment in both
responder and nonresponder samples are listed in Table S4.
Consistent with the GSEA result, many of the signature genes
are known to be erythroid speciﬁc, including genes encoding
globin proteins, red blood cell membrane proteins, and
enzymes critical for heme biosynthesis (Figure 1). Based on
these observations, we hypothesized that the lenalidomide
response signature was primarily one of erythroid differ-
entiation.
To validate the erythroid nature of the lenalidomide
response signature, we hypothesized that the response
signature should be induced as hematopoietic progenitor
cells are induced to differentiate along the erythroid lineage
in vitro. Accordingly, we monitored the expression of the
response signature in primary human CD34
þ hematopoietic
progenitor cells from normal adult bone marrow undergoing
erythroid differentiation using a two-phase liquid culture
system. Strikingly, the expression of all but one of the
signature genes increased dramatically during terminal
erythroid differentiation (Figure 2). This result further
indicates that the lenalidomide response signature relates to
erythroid differentiation.
Table 2. Comparison of the Clinical Characteristics of Lenalidomide Responders versus Nonresponders in the Training Set
Characteristic Responders (Mean 6 SD) n ¼ 8 Nonresponders (Mean 6 SD) n ¼ 8 p-Value
Age 64.8 6 13.2 73.0 6 7.3 0.14
Bone marrow blasts (%) 3.43 6 3.01 2.57 6 3.35 0.61
Bone marrow M:E ratio 2.03 6 2.55 1.66 6 0.69 0.70
Hemoglobin 8.74 6 1.22 9.15 6 0.95 0.46
White blood count 3.99 6 2.33 3.37 6 1.44 0.53
Absolute neutrophil count 1.95 6 1.07 1.95 6 0.98 0.99
Platelet count 288.8 6 159 287 6 215 0.99
The mean and standard deviations (SD) are listed for all values. p-Values were calculated by two-tailed Student t-test.
doi:10.1371/journal.pmed.0050035.t002
Table 1. Clinical Parameters for the Samples That Comprise the Training Set
Sample Source Resp Sex Age Hgb WBC ANC Platelet M:E Ratio WHO IPSS Blast Karyotype
6 Rush NR F 57 7.60 4.08 1.96 217 2.2 RARS Low 1.30 46,XX
9 Rush NR M 78 9.40 6.10 4.03 41 1.4 RCMD-RS Low 0.50 46,XY,del(20)(q11.2q13.3)
13 Rush NR m 79 9.50 1.37 0.59 279 2.0 RAEB-2 Int1 11.0 þAuer 46,XY,del(20)(q11.2q13.1)
17 Rush NR M 77 10.10 4.15 2.24 183 0.6 RARS Low 0.50 46,XY
19 Rush NR M 71 8.00 2.97 1.93 289 1.0 RAEB-1 Int1 8.50 46, XY
20 Rush NR M 72 8.90 2.27 1.48 232 2.8 MDS-U Int1 1.00 46,XY
22 Rush NR F 71 9.40 3.43 1.85 780 1.5 RA Int1 0.00 47,XX,þ15
24 Rush NR M 79 10.30 2.55 1.50 275 1.8 RAEB-1 Int1 6.20 47,XY,þ8
2 Rush R M 71 8.00 4.70 2.40 68 8.0 CMML-1 Int1 7.70 46,XY
4 Rush R M 78 8.70 5.82 3.49 453 1.0 RARS Low 0.40 46,XY
14 Rush R M 72 10.30 3.34 2.57 336 1.5 RAEB-1 Int1 7.20 46,XY
16 Rush R F 62 9.50 1.10 0.43 366 3.0 REAB-1 Int1 5.00 46,XX
21 Rush R F 58 6.80 4.38 2.93 411 0.6 RA Low 0.50 46,XX
23 Rush R F 36 10.20 2.57 1.29 412 0.6 RA Low 0.80 46,XX
25 Rush R F 72 8.60 8.25 1.65 218 1.1 CMML-1 Low 1.60 46,XX
7 Rush R M 69 7.80 1.74 0.80 46 0.4 RARS Int1 4.20 46,XY
Response (Resp) to lenalidomide is noted as responder (R) or nonresponder (NR). Clinical parameters include hemoglobin (Hgb, g/dl), white blood count (WBC, cells/ll), absolute
neutrophil count (ANC, cells/ml), platelet count (platelet, cells/ml), bone marrow myeloid to erythroid ratio (M:E ratio), World Health Organization (WHO) classification, international
prognosis scoring system (IPSS) designation, bone marrow blast percentage (Blast), and karyotype. WHO classifications are abbreviated RA for refractory anemia, RARS for refractory
anemia with ringed sideroblasts, RCMD for refractory cytopenia with multilineage dysplasia, RCMD-RS for refractory cytopenia with multilineage dysplasia and ringed sideroblasts, RAEB
for refractory anemia with excess blasts, and MDS-U for myelodysplastic syndrome–unclassified [35,36].
Int1, intermediate-1; Rush, Rush Medical School.
doi:10.1371/journal.pmed.0050035.t001
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Independent Set of Samples
One important challenge in the development of gene
expression-based predictors is ensuring that the predictors
continue to perform well when applied to an independent set
of samples. We therefore examined the behavior of the
erythroid differentiation signature (Table 3) in a new
collection of MDS patients for whom lenalidomide response
was known. The test set included samples from an additional
Figure 2. Expression of the Lenalidomide Response Signature during
Erythroid Differentiation
Gene expression profiles were obtained from human adult bone marrow
CD34
þ cells undergoing erythroid differentiation in vitro at days 2, 4, 7,
and 10. Genes are ranked in order of differential expression between day
2 versus day 10. The genes in this signature are coordinately expressed
during erythroid differentiation, from lower expression (blue) in
immature progenitor cells to higher expression (red) in terminal
erythroid differentiation. Some of the genes from Figure 2 are not
present in Figure 3 due to the greater number of probe sets on HG_U133
Plus 2.0 microarrays than HG_U133AAofAv2 microarrays. All genes are
listed in Table S3.
doi:10.1371/journal.pmed.0050035.g002
Figure 1. Gene Expression Signature of Lenalidomide Responsiveness
Rows correspond to the expression of different genes, and columns
correspond to different patient samples. The highest expression of each
gene across the samples is portrayed in dark red while the lowest
expression is shown in deep blue. Genes with well-documented roles in
erythroid differentiation are noted. All genes are listed in Table S2 along
with their associated signal-to-noise values, FDR, and fold change
between responders and nonresponders.
doi:10.1371/journal.pmed.0050035.g001
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deletions (Table 4). Among the patients without 5q deletions,
the test set had a higher proportion of patients with low-risk
International Prognostic Scoring System (IPSS) scores than
the training set (62% versus 44%).
GSEA indicated dramatic enrichment in responding versus
nonresponding patients across 26 patients (p , 0.001).
Importantly, the signature was highly correlated with
response among 13 patients lacking 5q deletions (p , 0.001)
(Figure 3). These ﬁndings are consistent with our initial
observation that decreased expression of the erythroid
differentiation signature correlates with lenalidomide re-
sponse.
Development of a Lenalidomide Response Predictor
We next sought to create a single score that could be used
to evaluate the expression of the response signature in
individual patients (as opposed to the dataset as a whole). To
create a robust score that is independent of the microarray
platforms, we normalized each gene to a panel of ﬁve control
genes, calculated a z-score for each gene, and computed an
average z-score for all genes in the sample (see Materials and
Methods). This average z-score metric accurately separated
responders from nonresponders in the training set (Figure
4A). The training set was also used to deﬁne a ‘‘no call’’ zone
representing predictions of low conﬁdence (Figure 4A). This
metric also separated responders from nonresponders using
the gene expression values obtained from a multiplexed PCR-
based assay (Figure S3).
We next applied the predictor without further modiﬁca-
tion to the 26 validation samples. High-conﬁdence predic-
tions were made on 22/26 patients (85%), 19 of which
correctly predicted lenalidomide response (86%)—far be-
yond what would be expected by chance (p ¼ 0.0015). The
predictor was similarly accurate within the subset of patients
lacking 5q deletions (Figure 4B): high-conﬁdence calls were
made in 11/13 patients, and 9/11 (82%) were classiﬁed
correctly (p ¼ 0.0186). Similarly, the predictor was highly
accurate among patients harboring 5q deletions (10/11
predicted correctly, Figure 5). Importantly, the one 5q
 
patient that failed to respond to lenalidomide was correctly
predicted to be a nonresponder, suggesting that a common
molecular phenotype (an erythroid differentiation defect)
underlies all responses to lenalidomide.
The demonstration that the gene expression signature
correctly predicted therapeutic response in an independent
set of samples acquired from multiple institutions validates
the ﬁnding that decreased expression of a set of genes that
are speciﬁc to terminal erythroid differentiation is associated
with response to lenalidomide.
Hematopoietic Effects of Lenalidomide In Vitro
The mechanism of action of lenalidomide in MDS is not
known, but immunomodulatory and antiangiogenic effects
have been observed in other systems [22]. Our observation
that an erythroid differentiation signature predicts response,
however, suggested an alternative hypothesis, namely that
lenalidomide has direct effects on the erythroid potential of
hematopoietic cells. To test this hypothesis, we treated
primary human adult bone marrow cells with lenalidomide
in vitro and evaluated the effects on hematopoietic differ-
entiation. In liquid culture containing cytokines that support
erythropoiesis, megakaryopoiesis, and myelopoiesis, low
doses of lenalidomide consistently promoted erythropoiesis
in culture (Figure 6A and 6B).
To determine whether lenalidomide activates the response
signature, we performed gene expression proﬁling on normal
CD34
þ cells cultured in the presence or absence of
lenalidomide for 24 h. The response signature had signiﬁ-
cantly higher expression in lenalidomide-treated cells (p ,
0.001 by GSEA, Figure S3).
In addition, we cultured adult human bone marrow cells on
methylcellulose following 3 d of treatment with lenalidomide
in liquid culture. Lenalidomide signiﬁcantly increased the
ratio of erythroid to granulocyte-monocyte colony-forming
units (Figure 6C and 6D). Thus, both liquid culture and
methycellulose colony assays demonstrate that lenalidomide
promotes erythropoiesis, consistent with the ﬁnding that the
patients who respond to the drug have the greatest defect in
erythroid differentiation.
Discussion
MDS is characterized by dysplastic differentiation and
apoptosis of hematopoietic progenitor cells for one or more
lineages [23–25]. Lenalidomide is known to induce hemato-
Table 3. Lenalidomide Gene Expression Response Signature
Gene Symbol Gene Name
ALDH5A1 Aldehyde dehydrogenase 5 family, member A1
TRAK2 Trafficking protein, kinesin binding 2
ERAF Erythroid associated factor
USP12 Ubiquitin specific peptidase 12
TMCC2 Transmembrane and coiled-coil domain family 2
SLC4A1 Solute carrier family 4, anion exchanger, member 1
CA1 Carbonic anhydrase I
TSPAN5 Tetraspanin 5
FAM117A Family with sequence similarity 117, member A
TBPL1 TBP-like 1
GSPT1 G1 to S phase transition 1
NSUN3 NOL1/NOP2/Sun domain family, member 3
OPTN Optineurin
EIF2C2 Eukaryotic translation initiation factor 2C, 2
PIGC Phosphatidylinositol glycan anchor biosynthesis, class C
EPB42 Erythrocyte membrane protein band 4.2
ANK1 Ankyrin 1, erythrocytic
GLRX5 Glutaredoxin 5 homolog (S. cerevisiae)
HBA2 Hemoglobin, alpha 2
HBLD2 HESB like domain containing 2
SELENBP1 Selenium binding protein 1
SNCA Synuclein, alpha (non A4 component of amyloid precursor)
GYPB Glycophorin B (MNS blood group)
NUDT4 Nudix (nucleoside diphosphate linked moiety X)-type motif 4
HBA1 Hemoglobin, alpha 1
SLC25A37 Solute carrier family 25, member 37
ALAS2 Aminolevulinate, delta-, synthase 2
FECH Ferrochelatase
HBB Hemoglobin, beta
MYL4 Myosin, light chain 4
The lenalidomide gene expression signature was defined as the genes that are expressed
more highly in nonresponders relative to responders in the training set (FDR   0.10) that
are present on both the U133 Plus 2.0 and U133A microarrays. The one gene that was not
increased during erythroid differentiation in vitro, SLC16A1, was excluded from the
signature.
doi:10.1371/journal.pmed.0050035.t003
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Lenalidomide Response Signaturelogic and cytogenetic responses in MDS patients with
deletions of Chromosome 5q, leading to its recent approval
by the Food and Drug Administration for these particular
patients [3–5]. Unfortunately, most MDS patients lack the 5q
 
abnormality, and lenalidomide response in these patients is
estimated at only 26%. Given the considerable side effects of
lenalidomide, identifying predictors of drug response is of
critical importance. We found that mononuclear cells from
bone marrow aspirates of patients who respond to lenalido-
mide have decreased expression of genes that are speciﬁc to
terminal erythroid differentiation, regardless of the presence
or absence of a 5q deletion. Moreover, we found that
lenalidomide acts directly on hematopoietic progenitor cells
to increase erythropoiesis relative to other lineages.
The erythroid speciﬁcity of the lenalidomide response
signature is consistent with the biology of the 5q
  syndrome
in MDS. Patients with the 5q
 syndrome have a severe anemia,
a normal or elevated platelet count, and a relatively preserved
neutrophil count [26,27]. The gene or genes on Chromosome
5q that block erythroid differentiation have not been
identiﬁed [26,28–30]. Our gene expression data indicate that
lenalidomide–responsive MDS patients lacking 5q deletions
have a defect in erythroid differentiation analogous to the
ineffective erythropoiesis in patients with 5q deletions,
indicating a possible commonality in the molecular basis of
MDS in patients who respond to lenalidomide.
The bone marrow of patients with MDS is heterogeneous,
Table 4. Clinical Parameters for the Samples That Comprise the Test Set
Sample Source Resp Sex Age HgB WBC ANC Platelet WHO IPSS Blast Karyotype
47 DFCI NR M 65 7.90 3.60 3.09 139 RA Low 3.00 46,XY
54 DFCI NR F 54 8.80 12.70 6.85 918 RA Low 4.00 46,XX
48 DFCI R F 38 10.80 4.50 0.72 355 RA Low 3.00 46,XX
3 Rush R M 70 9.80 8.19 7.21 140 RARS Low 1.80 46,XY
66 UMass NR F 67 11.4 11.8 7.32 391 RARS Int1 0.70 47,XX,þ8
69 UMass NR F 78 9.4 5.7 2.73 404 RARS Low 1.00 46,XX
72 UMass R M 57 12.0 4.10 2.58 96 RA Low 4.80 46,XY
75 UMass R M 65 9.8 8.70 4.96 568 RA Low 1.35 46,XY
76 UMass R M 55 9.1 5.40 2.86 208 RA Low 3.00 46,XY
77 UMass R M 64 10.8 1.50 0.54 36 RCMD Int2 0.00 45,XY,-7
78 UMass NR F 71 8.1 4.40 2.06 441 RARS Int1 1.00 46,XX,inv(9)(p11q13),9qhþ
65 UMass NR M 81 7.5 4.4 2.2 155 RARS Int1 2.00 46,XY,del(2)(p13),inv(5) (p13q33),add(13)
81 UMass NR M 65 8.2 1.90 1.19 50 RAEB-1 Int1 8.00 46,XY
27 Rush R F 82 8.90 5.10 3.11 183 5q
  Low 1.00 46,XX,del(5)(q13q33)
29 Rush R F 78 8.30 7.32 4.83 87 5q
  Int1 4.80 46,XX,del(5)(q15q33)
30 Rush R F 66 9.00 4.38 2.19 238 5q
  Low 3.40 46,XX,del(5)(q13q33)
51 DFCI R M 73 8.00 6.40 4.43 560 RAEB Int1 9.00 46,XY,del(5)(q22q34)
53 DFCI R M 72 9.70 4.90 3.33 393 5q
  Low 0.00 46,XY,del(5)q15q31)
62 Rush R F 75 9.70 2.83 1.49 112 RAEB-1 Int1 5.60 45,XX,del(5)(q13q33)
63 Rush R F 84 10.00 4.66 3.03 222 5q
  Low 2.40 46,XX,del(5)(q13q33)
64 Rush R F 79 8.00 5.31 3.18 975 5q
  Low 1.80 46,XX,del(5)(q15q33)
31 Rush R F 67 7.90 7.07 3.89 323 5q
  Low 0.30 46,XX,del(5)(q13q33)
32 Rush R F 64 10.50 4.54 1.68 299 CMML-1 Low 3.70 46,XX,del(5)(q22q33)
67 UMass R M 60 9.1 1.8 0.63 28 RAEB-1 Int2 8.00 45,XY,del(5)(q13q33),add(6)(p25),-14,del(20)(q11.2)
73 UMass NR F 65 9.9 3.50 0.66 52 RCMD Int2 3.0 45,47,XX,del(5)(q13q33),þ8,-9,add(14)(p10),
þ15,-17,-18,add(20)(q11.2),del(20)(q11.2q13.1),
þ22,þmar1,þmar2[cp17]
79 UMass R M 57 10.10 2.70 1.13 — RAEB-1 Int1 6.00 46,XY,del(5)(q13q33)
DFCI, Dana-Farber Cancer Institute; Int2, intermediate-2; UMass, the University of Massachusetts Medical School. Other abbreviations are the same as in Table 1.
doi:10.1371/journal.pmed.0050035.t004
Figure 3. Gene Set Enrichment Analysis Using the Response Signature
Expression of the response signature, defined in the training set of
samples, was analyzed in an independent test set of samples from MDS
patients without 5q deletions. GSEA is a nonparametric statistical
methodology that examines whether a set of genes, e.g., the response
signature, occur towards the top of a list of genes that is ranked
according to a class distinction. In this case, all genes on the microarray
were ranked by signal-to-noise ratio in order of their differential
expression between nonresponders and responders. Black bars at the
bottom of the figure indicate the location of genes in the response
signature within the ranked list. The running enrichment score is shown
in green. Nearly all of the genes in the erythroid response are expressed
more highly in the non-responder class and are at the top of the ranked
list of genes, resulting in a strong and statistically significant enrichment
score (p , 0.001).
doi:10.1371/journal.pmed.0050035.g003
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differentiation states. In some studies, this heterogeneity has
been partially mitigated by studying CD34
þ/CD38  cells or
the entire CD34
þ population. Variability in the puriﬁcation
of these populations would likely complicate a gene expres-
sion-based clinical diagnostic assay. Our analysis of bone
marrow mononuclear cells provides a quantitative integra-
tion of the gene expression for cells in all states of
differentiation. Speciﬁcally, we found decreased levels of
genes expressed during terminal erythroid differentiation, a
ﬁnding that would likely be less evident in CD34
þ cells.
Lenalidomide was developed as an analog of thalidomide
[22], reported to have immunomodulatory, anticytokine, and
antiangiogenic properties [31–34], but the mechanism of
lenalidomide activity in MDS has not been determined.
Clinically, lenalidomide increases red blood cell production
and causes neutropenia and thrombocytopenia [3,4]. Our
studies show that lenalidomide increases erythropoiesis
relative to myelopoiesis and megakaryopoiesis in vitro in
the absence of the bone marrow stromal cells that contribute
to the bone marrow microenvironment, suggesting that the
lenalidomide response is cell autonomous. Therapeutic
responses might be due to the promotion of differentiation
or the induction of apoptosis in cells bearing mutations that
disrupt normal erythropoiesis.
We have found that lenalidomide promotes erythropoiesis
and is most efﬁcacious in MDS patients with a block in
erythroid differentiation. Whereas most MDS patients with
5q deletions are likely to be treated with lenalidomide, our
results suggest that those patients without 5q deletions who
are likely to respond can be identiﬁed prior to treatment
using the erythroid gene expression signature. Notably,
despite the heterogeneity of MDS marrows, the signature
was predictive in total marrow mononuclear cells, further
suggesting that the approach could be feasibly implemented
in the clinical setting. These results suggest that further
Figure 4. Prediction of Lenalidomide Response Using the Response Signature
Each gene in the response signature was normalized to a reference signature and converted to a z-score. The heat maps depict the normalized
expression of each gene in the response signature. High expression is shown in red, and low expression is shown in blue. The box-and-whisker plots
below the heat maps depict the average z-scores for the response signature for each sample. The dotted lines indicate the zone in which no call can be
made between responder and nonresponder. In the training set (A), all samples are correctly separated by the predictor. In the test set (B), lenalidomide
response is correctly predicted nine out of 11 samples (82%), and no call could be made in two samples.
doi:10.1371/journal.pmed.0050035.g004
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Lenalidomide Response Signaturetesting of the predictive signature is warranted. These studies
also suggest that lenalidomide therapy be considered for
other disorders characterized by defects in erythroid matu-
ration, such as Diamond-Blackfan Anemia.
Supporting Information
Figure S1. Evaluation of the Lenalidomide Response Signature by
Ligation-Mediated Ampliﬁcation with Detection on Fluorescent
Microspheres
(A) As shown in the schematic diagram, ﬁrst strand cDNA is
generated from oligo-dT primers. Ligation-mediated ampliﬁcation
(LMA) probes that bind to adjacent sequences on a target cDNA are
ligated. Annealed probes from all genes are ampliﬁed in a single
multiplexed PCR reaction using T3 and cT7 primers. The cT7 primer
is biotinylated, and amplicons are labeled with streptavidin-coated
phycoerythrin (SAPE). The upstream primer for each gene has a
unique FlexMAP tag that is recognized by a capture probe on a
microsphere of unique ﬂuorescent color.
Found at doi:10.1371/journal.pmed.0050035.sg001 (103 KB PPT).
Figure S2. The Expression of Seven Genes in the Training Set of
Samples Was Determined by LMA Followed by Quantitation of
Amplicon Abundance on Luminex Microspheres
Consistent with the gene expression proﬁles determined by Affyme-
trix microarrays, the erythroid signature is expressed at lower levels
in all nonresponders than in responders. As with the microarray data,
the response of all samples was correctly predicted by gene
expression.
Found at doi:10.1371/journal.pmed.0050035.sg002 (109 KB PPT).
Figure S3. Gene Set Enrichment Analysis Using the Lenalidomide
Response Signature in Lenalidomide-Treated Cells
CD34
þ cells were cultured in the presence 1 nM lenalidomide or an
untreated control for 24 h. Each condition was performed in
triplicate. The expression of the lenalidomide response signature
was examined in these samples using GSEA. All genes on the
microarray were ranked by signal-to-noise ratio in order of their
differential expression between lenalidomide treatment and the
untreated control. Black bars at the bottom of the ﬁgure indicate the
location of genes in the response signature within the ranked list. The
running enrichment score is shown in green. Nearly all of the genes
in the lenalidomide response signature are expressed more highly in
the lenalidomide-treated cells and are at the top of the ranked list of
genes, resulting in a strong and statistically signiﬁcant enrichment
score (p , 0.001).
Found at doi:10.1371/journal.pmed.0050035.sg003 (89 KB PPT).
Figure S4. Conﬁdence Intervals for the Effects of Lenalidomide on
Hematopoietic Differentiation In Vitro
The results from Figure 6 in the main text are portrayed as a box-
and-whisker plot. The horizontal bars represent the median values,
rectangles represent the interquartile ranges, and error bars
represent the 95% conﬁdence intervals. Primary human bone
marrow CD34
þ cells were treated with lenalidomide.
(A) In cells cultured with cytokines that support erythroid and
megakaryocytic differentiation, low doses of lenalidomide increased
the number of erythroid (GlyA
þ) cells relative to megakaryocytic
(CD41
þ) cells.
(B) In cells cultured with cytokines that support erythroid and
myeloid differentiation, low doses of lenalidomide increased the
number of erythroid (GlyAþ) cells relative to megakaryocytic
(CD11b
þ) cells.
(C) Cells treated with lenalidomide were cultured for 3 d in liquid
culture and then plated on methylcellulose. The total number of
colony-forming units did not change signiﬁcantly. As shown in (D),
the ratio of erythroid (BFU-E) to myeloid (CFU-GM) colonies
increased with low doses of lenalidomide.
Found at doi:10.1371/journal.pmed.0050035.sg004 (87 KB PPT).
Text S1. An Erythroid Differentiation Signature Predicts Response to
Lenalidomide in Myelodysplastic Syndrome
Found at doi:10.1371/journal.pmed.0050035.sd001 (54 KB DOC).
Table S1. List of All .cel Files for Microarray Experiments
Found at doi:10.1371/journal.pmed.0050035.st001 (30 KB XLS).
Table S2. Signiﬁcant Markers of Responders and Nonresponders
from Figure
Found at doi:10.1371/journal.pmed.0050035.st002 (56 KB XLS).
Table S3. Lenalidomide Response Signature
Found at doi:10.1371/journal.pmed.0050035.st003 (28 KB XLS).
Table S4. Gene Sets Enriched in Responders and Nonresponders in
Test Set (Figure 3)
Found at doi:10.1371/journal.pmed.0050035.st004 (26 KB XLS).
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Figure 5. Prediction of Lenalidomide Response in a Cohort of MDS with
5q Deletions
Normalized expression of each gene in the response signature is shown
in the heat map. The box-and-whisker plots depict the average z-score
for each sample. Response to lenalidomide was correctly predicted in ten
out of 11 samples (91%).
doi:10.1371/journal.pmed.0050035.g005
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Editors’ Summary
Background. Myelodysplastic syndrome (MDS) is a group of disorders in
which the bone marrow (the spongy material found inside bones) does
not make enough healthy blood cells. Normally, immature cells in the
bone marrow called hematopoietic stem cells mature (differentiate) into
three types of blood cells: red blood cells (which carry oxygen around
the body; people with too few red blood cells are ‘‘anemic’’), white
blood cells (which fight off infections), and platelets (which prevent
bleeding by forming blood clots). In patients with MDS, the production
of these mature cell types is defective. In addition, immature cells called
leukemic blasts sometimes accumulate in the bone marrow and blood.
Thus, although MDS itself is not a type of cancer, it often develops into
leukemia (blood cancer). The cause of most cases of MDS, which affects
mainly elderly people, is not known. Its symptoms include tiredness and
breathlessness (signs of anemia), frequent infections, and easy bruising
or bleeding. Patients are usually given supportive care to relieve their
symptoms (for example, blood transfusions to top up their red blood
cells). Chemotherapy can sometimes delay the progression of MDS to
leukemia and a few patients can be helped with bone marrow
transplantation.
Why Was This Study Done? Recently, researchers have discovered that
some people with MDS respond very well to a drug called lenalidomide.
Three-quarters of patients whose MDS is characterized by the loss of a
small part of Chromosome 5 need fewer blood transfusions after being
given lenalidomide but only a quarter of people without this
chromosomal defect respond to the drug. Unfortunately, most patients
with MDS do not have this chromosome abnormality and there is no way
to predict which of these patients are likely to respond to lenalidomide.
Lenalidomide is a toxic drug that damages white blood cells and
platelets, so it is important not to give it to people who might not
benefit. In this study, the researchers have used gene expression
profiling (a technique that catalogs all the genes expressed by a cell) to
try to develop a way of predicting who will respond to lenalidomide
What Did the Researchers Do and Find? The researchers obtained pre-
treatment bone marrow samples from patients enrolled in two clinical
trials of lenalidomide and compared the gene expression profiles of the
bone marrow cells from the patients who subsequently responded to
the drug with the profiles of cells from nonresponding patients. In all, 47
genes were more highly expressed in nonresponders than in responders.
The researchers then asked whether the expression of any gene sets
(collections of genes that code for proteins that work in a single
pathway) was greater in the nonresponders than in the responders. This
analysis revealed a ‘‘signature’’ of lenalidomide response consisting of a
set of genes normally expressed during the differentiation of red blood
cells (an ‘‘erythroid differentiation signature’’). Decreased expression of
this signature was associated with a response to lenalidomide in an
independent set of patients (validation set). The researchers then used
the response signature and the original set of samples to develop a
single score that could distinguish individual responders from non-
responders. This score accurately predicted the response of three-
quarters of the patients in the validation set to lenalidomide. Finally, the
researchers showed that lenalidomide promotes the erythroid matura-
tion of normal human hematopoietic stem cells grown in dishes and
stimulates the expression of the lenalidomide response signature in
these cells.
What Do These Findings Mean? These findings indicate that patients
with MDS who respond to lenalidomide have defective red blood cell
differentiation. In addition, they suggest that it might be possible to use
the response signature to develop a test that can predict which patients
with MDS will benefit from treatment with lenalidomide. However, the
preliminary predictive test described here will need to be tested in many
more patients before it can be used as a routine clinical test. Finally, the
researchers’ last experiment suggests that lenalidomide may help people
with MDS because it induces red blood cell differentiation. Lenalidomide
therapy might, therefore be useful in other disorders in which red blood
cell maturation is defective, including some forms of anemia.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050035.
  See a related PLoS Medicine Perspective article
  The US National Cancer Institute provides information for patients
about myelodysplastic syndrome (in English and Spanish)
  The UK charity Cancerbackup provides information about
myelodysplastic syndrome
  The American Cancer Society and the Leukemia and Lymphoma
Society provide additional information about myelodysplastic syn-
drome
  The US Food and Drug Administration provides information for
patients on lenalidomide
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